SITC Conference 2019

Novel Drug Active in Anti-PD-1/L1 Resistant Tumors

NATIONAL HARBOR, Md. — A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed.

Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in one-third of the 49 patients on study. The activity included one complete response, one partial response, and four cases of prolonged disease stabilization in the 13 patients with advanced NSCLC.

Read Full Article